Abstract This study was performed to determine relations among concentrations of high-density lipoprotein (HDL) apolipoprotein (apo) A-I and apoA-II and lipoproteins with apoA-I only (LpA-I) and with both apoA-I and apoA-II (LpA-I:A-II) in patients with low plasma levels of HDL cholesterol. Seventyseven middle-aged men with low HDL cholesterol levels (<40 mg/dL) were compared with 37 middle-aged men with normal HDL cholesterol levels (>40 mg/dL). Low-HDL patients were divided into those with nonnotrigh/ceridemia (trigh/cerides <250 mg/dL; n=49) and hypertriglyceridemia (trigh/cerides £250 mg/dL; n=28). Total apoA-I and apoA-II concentrations and apoA-I levels in LpA-I were significantly lower in the two
T here is growing evidence 1 ' 2 and recognition 3 ' 4 of an inverse relation between levels of highdensity lipoprotein (HDL) and risk of coronary heart disease (CHD). This link has been most commonly identified by the increased CHD risk associated with a low HDL cholesterol (HDL-C) concentration, 1 -2 and low HDL-C has been designated as a major risk factor for CHD. 4 Moreover, a high HDL-C level appears to be "protective" against CHD. 4 Even so, HDL consists of several subtractions that may vary in their antiatherogenic potential, and the identification and differentiation of these subfractions could prove useful in CHD risk assessment in individual patients. For example, larger HDL particles (ie, HDL 2 ) appear to be more closely linked in an inverse way to CHD risk than do smaller HDL3 particles. 5 -7 Differences in antiatherogenic potential may also be related to the apolipoprotein concentrations and composition of HDL. Several reports 810 suggest that reduced concentrations of HDL apolipoproteins are associated with increased CHD risk. Furthermore, two types of HDL particles have been identified, ie, those having apolipoprotein (apo) A-I only (LpA-I) and those having both apoA-I and apoA-II (LpA-I:A-II). The HDL 2 subfraction is enriched in LpA-I, and LpA-I levels have a stronger inverse correlation with CHD risk than do LpA-I:A-II levels.
The present study was performed to specifically explore the relations among concentrations of total apoA-I, total apoA-II, and apoA-I in LpA-I and LpA-I:A-II in patients with low HDL-C levels. The following questions were addressed: (1) In patients with low HDL-C levels, are there equivalent reductions in total apolipoproteins (apoA-I and apoA-II)? (2) Is there a selective reduction in LpA-I compared with LpA-I:A-II? (3) Do these relations differ depending on whether patients have hypertriglyceridemia? And finally (4) , is there a selective reduction in LpA-I relative to LpA-I:A-II in low-HDL patients with CHD compared with low-HDL patients without CHD?
Methods

Patients
The primary group included 77 middle-aged (range, 31 to 69 years) men with low concentrations of HDL-C who were selected from the outpatient departments of the Veterans Affairs Medical Center (VAMC) and Parkland Memorial Hospital, Dallas, Tex. The patients' initial HDL-C was less than 40 mg/dL in the outpatient setting, but for entry into the study this level was confirmed as the mean of three values obtained on either the metabolic ward of the VAMC or the General Clinical Research Center at Parkland Memorial Hospital. Hypoalphalipoproteinemia was defined as HDL-C below 40 mg/dL on the basis of the finding of the Framingham Heart Study 12 that risk for CHD increases strikingly at HDL-C levels below this value. Another 37 middle-aged (range, 45 to 69 years) men were recruited as control subjects for the study. They were selected in the same way as the study subjects except that their HDL-C levels were greater than 40 mg/dL.
The clinical characteristics of the patients and control subjects are presented in Table 1 . The low-HDL patients were divided into two groups: those having triglyceride levels of less than 250 mg/dL were called normotrigryceridemic, and those with triglyceride levels of 250 mg/dL or greater were categorized as having hypertriglyceridemia. These definitions are consistent with consensus recommendations. 13 None of the patients were taking any hypolipidemic agents at the time of entry into the study, nor had they taken such drugs in the 4 months preceding entry. None of the patients reported alcohol abuse during this period. In the low-HDL groups, 41 patients had CHD based on a history of documented myocardial infarction, coronary artery bypass surgery (at least 6 months before entry), or angina pectoris confirmed by greater than 50% occlusion of one or more coronary arteries as determined by angiography. Among the low-HDL patients, 34 had a history of hypertension, 15 were taking /3-adrenergic-blocking agents (/3-blockers), and 31 were smokers. Patients were excluded if they had a history of congestive heart failure, endocrine disorders (including diabetes mellitus), or gastrointestinal or renal dysfunction. Among control subjects, none had a history of CHD or other significant diseases. Two control patients were smokers and had hypertension; none were taking /J-blockers.
AJ1 patients signed consent forms that were approved by the appropriate institutional review boards. The patients were on an ad libitum diet during the study.
Analysis of Plasma Lipids, Lipoproteins, and Apolipoproteins
All subjects underwent a 14-hour fast and then had 20 mL of blood drawn into tubes containing 1 mg/dL EDTA, 0.005% chloramphenicol, 0.005% gentamicin sulfate, 0.01% NaN 3 , and 100 IU/mL aprotinin. An aliquot of the plasma was used to determine levels of plasma total cholesterol, triglycerides, and lipoprotein cholesterol. Another aliquot was used to measure plasma levels of apoA-I, apoA-II, LpA-I, and LpA-I:A-II.
Total cholesterol and triglyceride concentrations in plasma were measured enzymatically.
14 ' 15 Levels of HDL-C were determined enzymatically after precipitation of apoB-containing lipoproteins with heparin-manganese. 16 Concentrations of plasma very-low-density lipoprotein (VLDL) cholesterol and low-density lipoprotein (LDL) cholesterol were estimated according to the equations of Meyers et al. 17 When plasma triglycerides exceeded 300 mg/dL, lipoprotein cholesterol levels were determined after ultracentrifugation according to Lipid Research Clinics methodology 16 except that all measurements were made enzymatically.
Plasma concentrations of apoA-I and apoA-II were determined by electroimmunoassay (EIA) using a modification of the method of Laurell. 18 For measurement of apoA-I, polyclonal anti-human apoA-I antisera were obtained from the Boehringer-Mannheim Corp (Biochemical Products). The electrophoresis gel consisted of 1.25% antisera, 2% (wt/vol) Seakem agarose (0.16 to 0.19 relative mobility electroendosmosis; Marine Colloids Division, FM Corp), 2% (wt/vol) dextran (molecular weight, approximately 70 000; Sigma Chemical Co), and a nonbarbital buffer. 19 The standard used was a serum calibrator for apoA-I obtained from Boehringer-Mannheim Diagnostics that was recalibrated in our laboratory by EIA using pure apoA-I as the primary standard. The interassay coefficient of variation was 6.7%, and the intra-assay coefficient of variation was 3.0%. For EIA determination of apoA-II, 2.0% agarose and 2.5% polyethylene glycol (molecular weight, 5000) were used. Anti-apoA-11 antisera were obtained from Boehringer-Mannheim Diagnostics, and the same serum calibrator that was used for EIA of apoA-I was employed in the apoA-II assay. The coefficient of interassay variation was 2.7%, and the intra-assay coefficient of variation was 1.9%.
LpA-I concentrations were determined by a modification of the method of Parra et al. 20 In this procedure, 2.5% Seakem agarose and 2.5% dextran (molecular weight, approximately 70 000) were used for EIA. One percent anti-human apoA-I sera and 15% anti-human apoA-II sera were incorporated into the EIA. These antisera concentrations caused complete precipitation of apoA-II-containing lipoproteins, and thus only apoA-I-containing lipoproteins were quantified. The primary standard for this assay was prepared as follows. A pool of HDL (density, 1.063 to 1.21 g/mL) was prepared from several plasma samples. Fractions of HDL were divided into aliquots and placed in Eppendorf tubes, and varying amounts of anti-human apoA-II were added to precipitate apoA-II-containing subfractions from the HDL pool. The tubes were incubated 48 hours at 4°C and centrifuged to sediment the antibody complex. The supernatants were collected and tested for immunoreactivity with anti-apoA-II by EIA. Those samples lacking any immunoreactivity against apoA-II were used to determine the amount of apoA-I by EIA. These samples were pooled as primary standards. The serum calibrator used in the EIA of apoA-I and apoA-II was calibrated to be used as a secondary standard for LpA-I. Concentrations of LpA-I:A-II were estimated as the difference between total plasma apoA-I and the apoA-I in LpA-I. The interassay coefficient of variation for the LpA-I assay was 3.6%, and the intra-assay coefficient of variation was 4.3%.
Statistical Analysis
A linear statistical program available in CUNFO on a VAX 750 was used for analysis of the data. ANOVA was used for comparison of the means of the three groups.
Results
Plasma lipids in the three groups of patients are shown in Table 2 . Total cholesterol levels were somewhat lower in normotriglyceridemic low-HDL patients and somewhat higher in hypertriglyceridemic low-HDL patients than in control subjects. In the normotriglyceridemic low-HDL group, average triglyceride levels were in the normal range but were nonetheless higher than in the control group. There were no differences in LDL cholesterol levels among the three groups, whereas HDL-C levels were lower in the two low-HDL groups.
Concentrations of plasma total apoA-I and apoA-II and of apoA-I in LpA-I and LpA-I:A-II are given in Table 3 . Total apoA-I and apoA-II levels were both significantly lower in the two low-HDL groups compared with the control group. ApoA-I levels in LpA-I were significantly different among all three groups (7><.001 by ANOVA). Both low-HDL groups had significantly lower apoA-I levels in LpA-I than control subjects; between the former two groups, levels were lowest in the normotriglyceridemic group. Although apoA-I levels in the LpA-I:A-II of both low-HDL groups were numerically lower than control subjects' levels, there were no significant differences between any pair of the three groups (P=.O75 by ANOVA). When low-HDL patients were divided into smokers and nonsmokers, there were no differences between the two groups (data not shown). The same was true for those taking and not taking /3-blockers. Table 4 summarizes percentage reductions of HDL parameters in the two low-HDL groups compared with values obtained for control subjects. In the low-HDL groups, HDL-C levels were decreased considerably more than were apoA-I levels in total plasma, LpA-I, and LpA-I:A-II. In both low-HDL groups, total apoA-II levels were decreased as much as total apoA-I levels or percentage reductions of apoA-I in the two lipoprotein subfractions. Table 5 compares the various parameters in patients with and without CHD. Two comparisons are shown: that for all patients combined and that for patients with low HDL-C. When all patients were pooled, patients with CHD had significantly higher levels of VLDL cholesterol and significantly lower levels of HDL-C, total apoA-I, and LpA-I. When only patients with low 'Significantly lower than control group values; P<.01 (see Table 3 ). tNot significantly different from control group values (see Table 3 ).
HDL-C were included, no differences were uncovered between those with and without CHD.
Discussion
The hypothesis that LpA-I is uniquely antiatherogenic was set forth by Puchois et al 11 in 1987. These investigators compared 50 patients with angiographically defined coronary artery disease (CAD) with 50 subjects who were negative for CAD by angiography. Patients with CAD had significantly lower levels of HDL-C and LpA-I than did CAD-negative patients; there were no significant differences in levels of total apoA-I or LpA-I:A-II.
n Puchois et al" concluded that even when levels of total plasma lipids are in the normal range, patients with coronary atherosclerosis are characterized by an abnormal distribution of apoA-I between LpA-I and LpA-I:A-II, ie, there appears to be a selective reduction in LpA-I particles. Thus, they speculated that LpA-I may represent the antiatherogenic fraction of HDL. More recently, Rader et al 21 quote unpublished results from the same laboratory that the plasma LpA-I level was the best single discriminating factor in a case-control study of lipids and lipoproteins in adolescent children of parents with premature CAD compared with matched control subjects; in this study, LpA-I:A-II had no discriminating value.
Since the study of Puchois et al, 11 several other reports have appeared on the interrelations among HDL lipid and apolipoprotein subtractions in coronary patients compared with control subjects. The results of these studies are summarized and compared with those of Puchois et al" in Table 6 . Coste-Burel et al 22 report roughly equivalent reductions in HDL-C, total apoA-I, LpA-I, and LpA-I:A-II in both CAD patients and control subjects. They conclude that abnormalities of LpA-I and LpA-I:A-II reflect metabolic disorders in patients with CHD but do not uniquely identify such patients; in particular, LpA-I levels were not a better discriminator than LpA-I:A-II levels. Genest et al 23 likewise report that both LpA-I and LpA-I:A-II levels are significantly reduced along with HDL-C and total apoA-I concentrations in a group of CHD patients compared with a control group. Parra et al 24 examined a large number of patients with CHD from France and Northern Ireland, and matched control subjects were obtained for both groups from the two countries. Comparisons between case and control subjects showed similar results for the two countries, and therefore the data are combined in Table 6 . CHD patients showed similar reductions in concentrations of HDL-C, apoA-I, and LpA-I levels compared with control subjects; LpA-I:A-II levels were also significantly reduced, but somewhat less than for the LpA-I indicates lipoproteins with apolipoprotein (apo) A-l only; LpA-l:A-ll, llpoproteins with both apoA-I and apoA-ll; HDL-C, high-density lipoprotein cholesterol; CAD, coronary artery disease; and CHD, coronary heart disease. CAD was documented by coronary angiography; CHD, by history of myocardial infarction. Values are expressed as milligrams per dedliter±SEM.
•Significantly different according to authors. tNot significantly different according to authors.
other parameters. Finally, Cheung et al, 25 in a small study, and Marques-Vidal et al, 26 in a preliminary report, indicate that LpA-I:A-II levels but not LpA-I levels are reduced in patients with CHD. Thus, the attractive hypothesis of Puchois et al 11 that LpA-I is uniquely predictive of CHD has not been strongly supported by subsequent studies 1822 ; nonetheless, further investigation into the potential antiatherogenic properties of this HDL subtraction seems warranted.
The present study was performed to address issues of apoA-I levels and the distribution of apoA-I between LpA-I and LpA-I:A-II in patients with low HDL-C levels. This category of patients was chosen for study because these issues have not been specifically addressed in low-HDL patients, who are known to be at high risk for CHD. Low HDL-C was defined as a level less than 40 mg/dL because of data from the Framingham Heart Study 12 showing a striking increase in risk for CHD below this level. Control subjects were matched for age and had HDL-C levels of 40 mg/dL or higher. The mean HDL-C level for the control group was therefore higher than the mean for the general male population of the same age because about 30% of American men in the age group under study have HDL-C levels of less than 40 mg/dL. 27 Low-HDL patients with normal trigrycerides and low-HDL patients with elevated triglycerides were studied; the aim was to determine whether apoA-I levels were different between these two types of low-HDL patients. As might be expected, more patients with low HDL-C levels had CHD than control subjects. Approximately 20% of the low-HDL patients took 0-blockers, in keeping with the relatively high use of /J-blockers among CHD patients. In the same way, approximately 40% of low-HDL patients were smokers. It is possible that cigarette smoking and use of /J-blockers may have contributed to low HDL-C levels in the low-HDL group, but whether they uniquely affect apoA-I metabolism is unknown. However, Genest et al 23 find no unique effect of -blockers on levels of LpA-I and LpA-I:A-II, and in a report from our laboratory, Gylling et al 28 observe no specific effects of cigarette smoking on apoA-I metabo-lism in patients with low HDL-C levels. Subgroup analysis of patients with and without these two potentially confounding factors uncovered no effect of either.
The first question addressed in the present study was whether patients with low HDL-C have parallel reductions in apoA-I and apoA-II levels. When patients were chosen on the basis of low HDL-C levels, the cholesterol levels in HDL were reduced more than those of either apoA-I or apoA-II, even though both apoA-I and apoA-II levels were significantly decreased (Table 4) . In previous investigations, 2226 HDL-C levels were reduced as much or more than apoA-I levels, but since patients in these investigations were not selected on the basis of low HDL-C, discrepancies between HDL-C and apoA-I levels were not as striking as in the present study. Of interest, apoA-II levels in our patients were decreased as much, if not more, than apoA-I levels. This finding indicated that the factors responsible for low HDL-C concentrations are not limited to the metabolism of apoA-I or LpA-I.
A second issue under investigation was whether low-HDL patients have a selective reduction of LpA-I compared with LpA-I:A-II. Puchois et al n raise this possibility because they report that there was a selective reduction in LpA-I levels in patients with CHD. Indeed, in both of our low-HDL groups, apoA-I levels in LpA-I were statistically significantly reduced compared with control subjects' concentrations (Tables 3 and 4) ; in contrast, LpA-I:A-II levels in the low-HDL groups were not significantly lower than control subjects' levels. There was a trend toward lower LpA-I:A-II levels in both low-HDL groups, but the reduction did not reach statistical significance in either group. The present results thus support the concept that when patients have a low HDL-C level, whether associated with hypertriglyceridemia or not, there is a preferential reduction of LpA-I compared with LpA-I:A-II. Nonetheless, the reduction in apoA-I levels may not be exclusively in LpA-I because of the trend toward a decrease in LpA-I:A-II. Furthermore, several other reports (References 18 through 22 and Table 6 ) do not confirm a selective reduction of LpA-I levels in patients with CHD (or CAD) as first proposed by Puchois et al. u Hypertriglyceridemia is a well-known cause of low HDL-C, 29 but the mechanisms whereby elevated triglycerides lower HDL-C levels are not fully understood. One mechanism appears to be an exchange between HDL-C esters and triglycerides of VLDL and chylomicrons; this exchange is mediated by cholesterol ester transfer protein. If this exchange were the only mechanism involved in hypertriglyceridemic patients, there would merely be a change in the nonpolar lipid composition of the core of HDL particles, and apoA-I and apoA-II levels would not necessarily be reduced with HDL-C. Hypertriglyceridemic low-HDL patients in this study, however, had a disproportionate reduction of HDL-C compared with apoA-I and apoA-II. However, the latter two apolipoproteins were also significantly lower than corresponding levels in control subjects. Therefore, additional mechanisms for a decrease in apoA-I levels of hypertriglyceridemic patients must be in effect. In fact, fractional clearance rates for apoA-I are increased in patients with elevated triglycerides, 30 and a recent report from our laboratory 28 indicates that hypertriglyceridemic low-HDL patients commonly have reduced lipoprotein lipase activity and increased hepatic triglyceride lipase activity. These additional factors could also contribute to reduced levels of apoA-I and apoA-II in patients with elevated triglycerides.
Finally, we examined our data to determine whether patients with CHD had a selective reduction in LpA-I levels. When all the subjects were separated into those with and without CHD, LpA-I levels were significantly reduced in CHD patients compared with those without CHD (Table 5) ; LpA-I:A-II concentrations were not significantly reduced. This observation is consistent with a selective reduction in LpA-I levels in CHD patients, although the patients of this study were not specifically chosen on the basis of the presence or absence of CHD. The finding of a selective reduction of LpA-I levels in CHD patients can therefore only be taken as suggestive, and it is not consistent with several other reports (Table  6 ). Thus, the present findings on this question must be taken within the frame of reference of this study.
When patients specifically selected for low HDL levels were divided into those with and without CHD, a greater reduction in LpA-I levels was not observed in CHD patients (Table 5 ). This observation could be of some importance. One possibility is that among patients with low HDL levels those at risk for CHD have a reduced LpA-I, whereas those not at risk have more normal LpA-I levels. However, the present data do not suggest that risk for CHD can be accurately predicted by levels of LpA-I in patients with low HDL-C.
The current study indicated that among low-HDL patients both apoA-I and apoA-II concentrations are decreased significantly. However, for most patients, neither apolipoprotein was lowered as much as was HDL-C. Although low levels of apoA-I 31 - 32 or LpA-I 11 may be better predictors for CHD than are HDL-C levels, this hypothesis is open to question because HDL-C levels could be reduced by atherogenic factors other than those affecting apoA-I metabolism. For example, in the presence of an increase in atherogenic remnants of triglyceride-rich lipoproteins, levels of HDL-C esters may be reduced by exchange with VLDL triglycerides; this exchange process need not necessarily lower apoA-I levels. Therefore, concentrations of HDL-C not only may reflect changes in metabolism of HDL particles but also may signify the presence of other atherogenic factors, such as an excess of remnant lipoproteins. Consequently, HDL-C levels could be a better overall indicator of CHD risk than are specific changes in HDL apolipoproteins, even though the latter may be more directly linked to atherogenesis.
In summary, the current study indicated that in patients with low HDL-C concentrations, LpA-I levels are reduced more than LpA-I:A-II concentrations. Whatever factors are responsible for low HDL-C levels, they apparently affect LpA-I more than LpA-I:A-II. Previous investigations 28 3° report that most low-HDL patients have an increase in the fractional clearance of apoA-I, and Rader et al 21 report that fractional clearance rates of LpA-I exceed those of LpA-I:A-H. Therefore, pathological processes that enhance the clearance of apoA-Icontaining particles probably affect LpA-I to a greater extent than LpA-I:A-II and account for the preferential reduction in LpA-I concentrations in patients with low HDL-C levels. Even so, these factors may not uniquely affect LpA-I particles; apoA-II concentrations were also reduced in the present study, and other investigators (Table 6 ) report parallel reductions in LpA-I:A-II in patients with low LpA-I concentrations.
Finally, an important but unresolved issue is whether LpA-I is uniquely responsible for the initiation of reverse cholesterol transport. Barbaras et al 33 report that LpA-I mediates the efflux of cholesterol from OB1771 cells, a mouse preadipocyte line, whereas LpA-I:A-I1 not only fails to promote cholesterol efflux but actually inhibits the removal of cholesterol from these cells by LpA-I. This finding, however, has not been confirmed in other cells. Johnson et al 34 have found that LpA-I and LpA-I:A-II are equally effective in removing cholesterol that originates in either the plasma membranes or lysosomes in several types of mammalian cells. Thus, further investigations are needed to determine the relative efficacies of LpA-I and LpA-I:A-II in reverse cholesterol transport.
